Novavax Stock Price | NVAX Stock Quote, News, and History

Feb. 04 2021 Mar. 05 2021 Download Reset Price change over selected period: 0% 0 Total Analysts: 11 Buy Ratings: 7 Neutral Ratings: 2 Sell Ratings: 2 Analyst: {{ANALYST_DATA}}Price-Target: {{PRICE_DATA}}Rating: {{RATING_DATA}}

Feb. 04 2021 Mar. 05 2021

Download Reset

Loading..
DateOpenCloseDaily HighDaily Low

Price change over selected period: 0% 0

Total Analysts: 11

Buy Ratings: 7 Neutral Ratings: 2 Sell Ratings: 2

Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}

Price *Price Target

Lowest: 8.00 Median: 45.73 Highest: 110.00

All
  • All
  • Buy
  • Hold
  • Sell
  • Yearly
  • Quarterly
 20242025202620272028
Revenue-666522606719
Dividend0.000.00---
Dividend Yield (in %)0.00 %0.00 %---
EPS--0.280.040.47
P/E Ratio32.7446.6143.73311.2526.77
EBIT81415635119
EBITDA17-106-12--
Net Profit723142-266
Net Profit Adjusted484841-129-75
Pre-Tax Profit78365335119
Net Profit (Adjusted)-178-427---
EPS (Non-GAAP) ex. SOE0.250.410.26-0.78-0.45
EPS (GAAP)--0.280.040.47
Gross Income810644527654785
Cash Flow from Investing56-51-34-679
Cash Flow from Operations23523107165234
Cash Flow from Financing56-51-34-679
Cash Flow per Share0.36-0.150.71--
Free Cash Flow27174107--
Free Cash Flow per Share-----
Book Value per Share-5.95-5.29-4.06--
Net Debt-709-745-838--
Research & Development Exp.394278213251260
Capital Expenditure166778
Selling, General & Admin. Exp.342164122--
Shareholder’s Equity-883-828-640--
Total Assets1,8611,8981,997--
 Previous Quarter
ending 06/30/24		Current Quarter
ending 09/30/24		Next Quarter
ending 12/31/24		Current Year
ending 12/31/25		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts44442
Average Estimate1.665 USD-0.858 USD0.353 USD0.285 USD0.040 USD
Year Ago0.649 USD-1.264 USD-1.442 USD--
Publish Date8/8/202411/6/20243/4/2025--
Revenue Estimates
No. of Analysts44454
Average Estimate465 USD71 USD333 USD666 USD522 USD
Year Ago424 USD187 USD291 USD--
Publish Date8/8/202411/6/20243/4/2025--

* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

DateNameDividend*yieldCurrency
2023Novavax Inc.0.000.00USD
2022Novavax Inc.0.000.00USD
2021Novavax Inc.0.000.00USD
2020Novavax Inc.0.000.00USD
2019Novavax Inc.0.000.00USD
2018Novavax Inc.0.000.00USD
2017Novavax Inc.0.000.00USD
2016Novavax Inc.0.000.00USD
2015Novavax Inc.0.000.00USD
2014Novavax Inc.0.000.00USD
2013Novavax Inc.0.000.00USD
2012Novavax Inc.0.000.00USD
2011Novavax Inc.0.000.00USD
2010Novavax Inc.0.000.00USD
2009Novavax Inc.0.000.00USD

*Yield of the Respective Date

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Risk
  • Low
  • Medium
  • High

Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’sbalance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of creditrisk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes intoaccount day-to-day movements in market value compared to a company’s liability structure.

Ownerin %
Freefloat94.96
State Street Corp.12.04
Vanguard Group, Inc. (Subfiler)9.41
Shah Capital Management, Inc.7.81
Shah Capital Management, Inc.5.78
SK bioscience Co., Ltd.4.63
SSgA Funds Management, Inc.4.32
BlackRock Fund Advisors3.71
Vanguard Total Stock Market ETF3.03
Vanguard Small Cap Index Fund2.39
BlackRock Institutional Trust Co. NA2.28
SPDR S&P Biotech ETF1.93
iShares Russell 2000 ETF1.89
Geode Capital Management LLC1.84
Vanguard Extended Market Index Fund1.52

Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

ncG1vNJzZmilkae4psDSZ5muq5mjsrS%2FyKeqopyVp3uku8xoqq2nk6DAcLrVmq9mq6SksKw%3D

 Share!